X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MDR-101, is a single-dose cellular therapy derived from a living kidney donor’s blood. The therapy is designed to establish mixed chimerism, which occurs when a low level of donor blood cells remains in the blood of the kidney recipient after infusion of donor stem cells.
Lead Product(s): MDR-101
Therapeutic Area: Immunology Product Name: MDR-101
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
MDR-101 is a single-dose cellular therapy derived from a living kidney donor’s blood. This is the first randomized, multi-center pivotal study specifically designed to eliminate the use of immunosuppressive anti-rejection drugs following transplant.
Lead Product(s): MDR-101
Therapeutic Area: Immunology Product Name: MDR-101
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2021
Details:
MDR-101 is intended to induce donor-specific immune tolerance in order to avert transplant kidney rejection to minimize cumulative and serious side effects associated with immunosuppressive drugs.
Lead Product(s): MDR-101
Therapeutic Area: Immunology Product Name: MDR-101
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2021
Details:
The presentation will review the safety and efficacy of cellular immunotherapy with MDR-101 for induction of functional immune tolerance in recipients of human leukocyte antigen (HLA)-matched, living donor kidney transplants.
Lead Product(s): MDR-101
Therapeutic Area: Immunology Product Name: MDR-101
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2020
Details:
MDR-101 is being developed to avert transplant kidney rejection by the recipient’s immune system without the need for chronic use of immunosuppressive drugs.
Lead Product(s): MDR-101
Therapeutic Area: Immunology Product Name: MDR-101
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
